Is supernus a good company?

Is supernus a good company?

Is Supernus Pharmaceuticals a good company to work for? Supernus Pharmaceuticals has an overall rating of 3.3 out of 5, based on over 71 reviews left anonymously by employees. 58% of employees would recommend working at Supernus Pharmaceuticals to a friend and 44% have a positive outlook for the business.

How many employees does supernus pharmaceuticals have?

Compare SUPN With Other Stocks

Supernus Pharmaceuticals Annual Number of Employees
2019 464
2018 448
2017 422
2016 363

Is supernus a public company?

ROCKVILLE, Md. , May 4, 2012 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) (the “Company”), today announced the closing of its initial public offering of 10,000,000 of its common stock at a price of $5.00 per share.

How big is supernus pharmaceuticals?

EV. Supernus Pharmaceuticals’s current market capitalization is $1.5 b.

Where is supernus Pharmaceuticals located?

Supernus Pharmaceuticals, Inc 9715 Key West Ave Rockville, MD Pharmaceutical Consultants – MapQuest.

Who owns supernus?

BlackRock Institutional Trust Company, N.A.

What drugs does supernus make?

Products utilizing our technologies. These technologies have been utilized to create ten marketed products, including Trokendi XR® and Oxtellar XR® (Supernus), Adderall XR®, Intuniv®, and Mydayis® (developed for Shire, now Takeda), and Orenitram® (developed for United Therapeutics Corporation).

What happened to Adamas Pharmaceuticals?

Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals. ROCKVILLE, Md. , Nov. 24, 2021 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc.

Who bought Adamas?

Following the completion of the Offer, Supernus completed the acquisition of Adamas through the merger of Reef with and into Adamas, without a vote of Adamas stockholders in accordance with Section 251(h) of the General Corporation Law of the State of Delaware (DGCL), with Adamas surviving the merger as a wholly-owned …

Who bought Adamas Pharmaceuticals?

Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. entered a definitive agreement to acquire Adamas Pharmaceuticals, Inc. for approximately $400 million, plus two non-tradable contingent value rights (CVR) collectively worth up to approximately $50 million, based on GOCOVRI sales.